GlassScriptPhysician profile
Kevin C Harbour
NPI 1508903626
$12,827.63
in general payments reported to CMS, 2019-2025
43 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,351 · 2020: $279 · 2021: $845 · 2022: $1,087 · 2023: $5,967 · 2024: $1,511 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,912 · Education: $3,026 · Travel and Lodging: $1,029 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,911.80 |
| Education | $3,025.70 |
| Travel and Lodging | $1,028.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,707.66 | 2023 | Da Vinci Surgical System, Da Vinci Sp |
| Glaxosmithkline, LLC. | $1,494.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,148.47 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $957.85 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $336.72 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $320.68 | 2019-2025 | Zerbaxa, Recarbrio, Keytruda |
| Jazz Pharmaceuticals INC. | $302.07 | 2019-2025 | |
| Insmed, INC. | $293.73 | 2019-2025 | Arikayce |
| Genzyme Corporation | $283.83 | 2019-2025 | |
| Harmony Biosciences LLC | $275.60 | 2021-2025 | Wakix |
| Sunovion Pharmaceuticals INC. | $228.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $190.15 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $182.92 | 2024-2025 | Dupixent |
| Csl Behring | $172.88 | 2019-2021 | |
| Genentech USA, INC. | $159.90 | 2019-2023 | Xolair |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $152.19 | 2021-2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $148.25 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $148.05 | 2019-2024 | |
| Viatris Specialty LLC | $121.27 | 2025 | Yupelri |
| Amgen INC. | $120.20 | 2022-2025 | Tezspire |
| Tetraphase Pharmaceuticals, INC. | $118.52 | 2019 | |
| Grifols USA, LLC | $97.19 | 2019-2025 | Prolastin-C Liquid |
| Electromed, INC. | $85.10 | 2024-2025 | Smartvest |
| Body Vision Medical INC. | $66.86 | 2024 | Lungvision |
| Gilead Sciences, INC. | $61.90 | 2019-2021 | |
| Veran Medical Technologies, INC. | $60.20 | 2019 | |
| Mylan Specialty L.P. | $59.61 | 2023-2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $59.08 | 2024-2025 | Purified Cortrophin Gel |
| La Jolla Pharmaceutical Company | $54.33 | 2019-2024 | Giapreza |
| Pulmonx Corporation | $52.48 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Medtronic, INC. | $44.00 | 2023 | Illumisite |
| Philips North America LLC | $43.45 | 2019-2020 | |
| Verona Pharma, INC. | $42.48 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $42.31 | 2020-2022 | |
| 3b Medical, INC. | $31.85 | 2024-2025 | Luna |
| Teleflex LLC | $30.76 | 2025 | Orsiro Mission |
| Mallinckrodt Enterprises LLC | $28.62 | 2019 | |
| Shionogi INC | $24.20 | 2022 | |
| Fisher & Paykel Healthcare INC | $21.12 | 2025 | Fisher & Paykel Healthcare |
| Aerin Medical INC. | $16.73 | 2022 | |
| Pfizer INC. | $15.62 | 2022 | |
| Vifor Pharma, INC. | $14.01 | 2024 | Zemaira |
| Monaghan Medical Corporation | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Harbour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.